Company profile

Robert A. Bradway
Incorporated in
Fiscal year end
Former names
IRS number

AMGN stock data

FINRA relative short interest over last month (20 trading days) ?


1 May 20
4 Jun 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 6.16B 6.2B 5.74B 5.87B
Net income 1.83B 1.7B 1.97B 2.18B
Diluted EPS 3.07 2.85 3.27 3.57
Net profit margin 29.62% 27.48% 34.30% 37.11%
Operating income 2.36B 2.05B 2.48B 2.68B
Net change in cash 41M 51M -15M -8M
Cash on hand 718M 677M 626M 641M
Cost of revenue 1.51B 1.25B 1.04B 1.01B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 23.36B 23.75B 22.85B 22.99B
Net income 7.84B 8.39B 1.98B 7.72B
Diluted EPS 12.88 12.62 2.69 10.24
Net profit margin 33.57% 35.35% 8.66% 33.59%
Operating income 9.67B 10.26B 9.97B 9.79B
Net change in cash 97M 71M 51M 52M
Cash on hand 677M 580M 509M 458M
Cost of revenue 4.36B 4.1B 4.07B 4.16B

Financial data from Amgen earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
20 May 20 Ronald D Sugar Common Stock Sell Dispose S 229.27 1,000 229.27K 15,482
20 May 20 Ronald D Sugar Common Stock Option exercise Aquire M 54.69 1,000 54.69K 16,482
20 May 20 Ronald D Sugar Nqso Common Stock Option exercise Dispose M 54.69 1,000 54.69K 8,000
5 May 20 Austin Wanda M Common Stock Grant Aquire A 0 846 0 3,194
5 May 20 Eckert Robert Common Stock Grant Aquire A 0 846 0 12,031
5 May 20 Druker Brian Common Stock Grant Aquire A 0 846 0 2,719
5 May 20 Garland Greg C. Common Stock Grant Aquire A 0 846 0 9,024
75.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1958 2053 -4.6%
Opened positions 100 297 -66.3%
Closed positions 195 99 +97.0%
Increased positions 763 657 +16.1%
Reduced positions 838 820 +2.2%
13F shares
Current Prev Q Change
Total value 90.01B 109.76B -18.0%
Total shares 444.39M 456.37M -2.6%
Total puts 4.78M 6.36M -24.8%
Total calls 4.97M 5.54M -10.3%
Total put/call ratio 1.0 1.1 -16.2%
Largest owners
Shares Value Change
Vanguard 49.65M $10.06B +2.4%
BLK BlackRock 46.46M $9.42B +0.4%
Capital Research Global Investors 33.11M $6.71B -6.3%
STT State Street 26.21M $5.31B -0.1%
Primecap Management 18.48M $3.75B +1.0%
FMR 17.65M $3.58B -27.9%
Geode Capital Management 10.12M $2.05B +0.9%
NTRS Northern Trust 7.98M $1.62B -0.5%
BAC Bank of America 7.8M $1.58B +3.4%
MS Morgan Stanley 7.26M $1.47B +7.4%
Largest transactions
Shares Bought/sold Change
FMR 17.65M -6.84M -27.9%
Norges Bank 0 -6.29M EXIT
Clearbridge Advisors 4.12M +2.48M +151.2%
Capital Research Global Investors 33.11M -2.23M -6.3%
GS The Goldman Sachs Group, Inc. 3.24M -1.36M -29.6%
Johanson Financial Advisors 5.36K -1.21M -99.6%
JPM JPMorgan Chase & Co. 4.5M +1.18M +35.5%
Vanguard 49.65M +1.17M +2.4%
Advisor 974.28K +974.28K NEW
Capital International Investors 5.7M +933.19K +19.6%

Financial report summary

Management Discussion
  • * Change in excess of 100%.
  • Future sales of our products will depend in part on the factors discussed below and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2019: (i) Item 1. Business—Marketing, Distribution and Selected Marketed Products, (ii) Item 1A. Risk Factors and (iii) Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview, and Results of Operations—Product Sales, as well as in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, in Part II, Item 1A. Risk Factors.
  • The slight increase in ENBREL sales for the three months ended March 31, 2020, was driven by favorable changes to estimated sales deductions and inventory, offset by lower unit demand and net selling price. For the remainder of 2020, we expect the trend of lower unit demand to continue.
Content analysis ?
H.S. sophomore Avg
New words: AABP, acknowledged, adalimumab, Adaptive, adult, advice, Aid, anniversary, Annora, antibody, antiresorptive, Arthrex, backlog, BeiGene, build, cancellation, capacity, celebrating, China, chronic, Cir, combat, compulsory, conclusion, confirmatory, construing, consultation, coordinated, customer, cybersecurity, deCODE, dedesignate, Defense, degree, diagnosed, diagnostic, disposable, dissemination, distancing, downturn, ease, elderly, enrolled, enrollment, equal, equally, ESA, essential, exacerbate, exceeded, Fed, flexibility, fluidity, globe, goal, griffith, Hetero, hospital, hypothetical, Icelandic, immunomodulatory, immunosuppressive, incident, inequitable, infection, influence, internationally, investee, Japanese, joining, Judge, KANJINTI, Keytruda, labor, legacy, low, Magistrate, magnitude, mandate, Markman, medical, minimize, mitigate, mitigation, modification, monetization, month, movement, MSP, MVASI, navigate, Nephew, NIVESTYMTM, outbreak, ownership, pandemic, passage, pause, paused, pediatric, peter, precipitate, premium, prepaid, presence, procurement, produce, prolonged, proportionate, protocol, rapid, reassessment, recession, redemption, regular, remanded, remanding, remeasurement, remote, remotely, renamed, repaid, representation, rescheduled, retaliatory, revert, satisfaction, scope, screening, shareholder, Singapore, size, slightly, Smith, sotorasib, spread, Stafford, stakeholder, Stivarga, strain, strategy, subset, suspended, suspending, Switzerland, temporarily, trajectory, transfer, transferred, transferring, transmission, travel, trend, turn, uncertain, uncertainty, unclean, unemployment, Unichem, unpaid, unpredictable, upcoming, venture, Vice, voting, wider, widespread, workforce, worsen
Removed: AAA, abandoned, AbbVie, adjusted, ANDA, announced, antitrust, Apotex, application, applied, arising, asserted, assistance, Aventisub, borrowing, carry, cinacalcet, claim, classification, classified, commencement, commercially, component, composed, creating, defendant, denying, direct, disclose, discount, discretion, efficient, enforcement, enhance, estate, etelcalcetide, exclude, exercise, expired, failure, formulation, fund, FZE, impaired, implementation, implicit, incremental, indefinitely, inflation, innovation, invalid, invalidity, IPR, issue, Johnston, KANJINTITM, Kashiv, launch, lease, leasing, lifted, Lori, maintaining, marketing, molecule, mortgage, multiple, MVASITM, Mylan, network, noncancelable, noncurrent, nonlease, Northern, offer, ordered, package, Parsabiv, Pennsylvania, permitted, prepayment, prospective, protection, purported, putative, real, Regeneron, reinvest, renew, renewal, rental, repatriation, represent, repurchased, residual, resolved, responded, retained, revalue, reviewed, ROU, Sensipar, set, small, space, stay, stayed, sublease, Sun, terminate, therapy, undistributed, vacate, vehicle, Watson